# Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

Source: https://onco.cc/trials/nct06136624/  
OnCo record `nct06136624` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing Opevesostat in prostate cancer, now recruiting.

## Summary

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) is a phase 3 interventional study registered as NCT06136624, led by Merck Sharp & Dohme, and recruiting on the registry. Official title: A Phase 3 Randomised, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy (OMAHA-003). Planned enrolment is 1310 participants (estimated). The study started in 2023-12-31 and primary completion is expected in 2028-08-02. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Also known as: OMAHA-003
- Tags: ctgov-ingest
- Registry id: NCT06136624
- Phase: 3
- Setting: A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy (OMAHA-003)
- Sponsor: Merck Sharp & Dohme
- Enrolled: 1310

## Sources

- ClinicalTrials.gov NCT06136624: https://clinicaltrials.gov/study/NCT06136624

## Connected records

- cancers: [Metastatic castration-resistant prostate cancer](https://onco.cc/cancers/prostate-mcrpc/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [Opevesostat](https://onco.cc/drugs/opevesostat/)
- companies: [Merck & Co. (MSD)](https://onco.cc/companies/merck/)

---
JSON: https://onco.cc/api/v1/entities/nct06136624.json